SpyGlass Pharma: Vensana Capital I distributes 331K shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
SpyGlass Pharma, Inc. (SGP) is the issuer in an amendment reporting that Vensana Capital I, L.P. made a 331,036-share pro rata distribution on November 16, 2026, to Vensana Capital I GP, LLC and its limited partners without additional consideration. Vensana Capital I GP, LLC then made a pro rata distribution of 8,634 shares it received to its members, also without additional consideration.
The cover pages separately report beneficial ownership of 2,979,595 shares for Vensana Capital I GP, LLC; 2,979,583 for Vensana Capital I, L.P.; 2,989,621 for Kirk Nielsen, a member of SGP’s board; and 2,981,249 for Peter Justin Klein, a managing director of the general partner. Each is listed as 8.9% of the class, based on 33,461,450 shares outstanding as of November 2, 2026. These totals overlap: Vensana I’s shares are also attributed as shared voting and dispositive power to its general partner and the managing directors.
Filing Explained
This amendment adds that Vensana’s reporting persons reserve the ability to acquire or dispose of shares and intend to review their investment; that states future flexibility, not a committed purchase or sale.
Key Figures
Key Terms
pro rata distribution financial
beneficially owned regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of SGP did the reporting persons beneficially own?
AI-generated analysis. How Rhea-AI works. Not financial advice.